In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The pharmaceutical company will build six new production sites and one for research and development in the USA. This will ...

Novartis has over 3,000 employees working at its campus in East Hanover, and 12,000 employees nationwide, said Novartis ...

Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by the US regulator last year – and has set a new action date of 1 ...

Novartis' cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE.

As for the other cardio drugs at the heart of Novartis’ new commercial strategy, Leqvio—approved in December 2021 to help lower levels of bad cholesterol in patients who’ve failed to do so ...

Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.